-
1.发明公开METHODS AND COMPOSITIONS FOR GENERATING CHONDROCYTE LINEAGE CELLS AND/OR CARTILAGE LIKE TISSUE 审中-公开方法和组合物GENERATING CHONDROZYTENZELLLINIEN和/或组织软骨
公开(公告)号：EP2981606A4
公开(公告)日：2016-08-10
申请号：EP14778943
申请日：2014-04-02
Applicant: UNIV HEALTH NETWORK
Inventor： KELLER GORDON , CRAFT APRIL M
CPC classification number: A61K35/32 , C12N5/0655 , C12N2501/115 , C12N2501/155 , C12N2501/16 , C12N2501/415 , C12N2501/999 , C12N2503/02 , C12N2506/02 , C12N2506/03 , G01N33/5044
Abstract: A method for generating chondrocytes and/or cartilage, optionally articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue and/or hypertrophic chondrocyte like cells and/or cartilage like tissue, the method comprising: a. culturing a primitive streak-like mesoderm population, optionally a CD56+, PDGFRalpha+ KDR-primitive streak-like mesoderm population, with a paraxial mesoderm specifying cocktail comprising: i. a FGF agonist; ii. a BMP inhibitor; optionally Noggin, LDN-193189, Dorsomorphin; and iii. optionally one or more of a TGFbeta inhibitor, optionally SB431524; and a Wnt inhibitor, optionally DKK1, IWP2, or XAV939; to specify a paraxial mesoderm population expressing cell surface CD73, CD105 and/or PDGFR-beta; b. generating a chondrocyte precursor population comprising: i. culturing the paraxial mesoderm population expressing CD73, CD105 and/or PDGFR-beta at a high cell density optionally in serum free or serum containing media; ii. culturing the high cell density CD73+, CD105+ and/or PDGFRbeta+ paraxial mesoderm population with a TGFbeta3 agonist in serum free media to produce a high cell density Sox9+, collagen 2+ chondrocyte precursor population; and c. either i. culturing the high cell density Sox9+, collagen 2+ chondrocyte precursor population with the TGFbeta3 agonist for an extended period of time to produce an articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue; or ii. culturing the high cell density Sox9+ collagen2+ chondrocyte precursor population with a BMP4 agonist for an extended period of time to produce a hypertrophic chondrocyte like cells and/or cartilage like tissue.
-
2.发明公开METHODS AND COMPOSITIONS FOR GENERATING PANCREATIC PROGENITORS AND FUNCTIONAL BETA CELLS FROM hPSCs 审中-公开方法和组合物胰脏前体和功能性β细胞FROM HPSCS
公开(公告)号：EP2844739A4
公开(公告)日：2015-12-02
申请号：EP13784648
申请日：2013-04-30
Applicant: UNIV HEALTH NETWORK
Inventor： KELLER GORDON , NOSTRO MARIA CRISTINA , HOLTZINGER AUDREY , SARANGI FARIDA
CPC classification number: C12N5/0678 , A61K35/39 , C12N5/0676 , C12N2500/38 , C12N2501/11 , C12N2501/115 , C12N2501/119 , C12N2501/155 , C12N2501/385 , C12N2501/40 , C12N2501/415 , C12N2502/28 , C12N2506/02 , C12N2506/45
Abstract: Methods and compositions for producing NKX6-1+ pancreatic progenitor cells and/or insulin producing cells from an endodermal cell population, the method comprising contacting the endodermal cell population with an EGF component, a Nicotinamide component and/or a Noggin component, optionally a combination of at least one EGF component and at least one nicotinamide component to induce the differentiation of at least one endodermal cell into a NKX6-1+ pancreatic progenitor cell, the combination optionally further comprising at least one Noggin component.
Abstract translation: 方法和组合物，用于从内胚层细胞群体生产NKX6-1 +胰腺祖细胞和/或胰岛素产生细胞，所述方法包括用在EGF成分，烟酰胺组分和/或组件，头蛋白，任选的组合接触的内胚层细胞群 中的至少一个EGF成分和至少一种烟酰胺组分以诱导至少一个内胚层细胞分化成胰腺祖细胞NKX6-1 +，所述组合任选地进一步包含至少一种组分头蛋白。
-
3.发明公开
公开(公告)号：EP3259348A4
公开(公告)日：2018-07-18
申请号：EP16751855
申请日：2016-02-17
Applicant: UNIV HEALTH NETWORK
Inventor： KELLER GORDON , PROTZE STEPHANIE
CPC classification number: A61K35/34 , C12N5/0657 , C12N5/10 , C12N2501/115 , C12N2501/15 , C12N2501/155 , C12N2501/16 , C12N2501/165 , C12N2501/385 , C12N2501/727 , C12N2501/999 , C12N2506/02 , C12N2506/45
Abstract: Provided are methods for producing compositions comprising a population of cardiomyocytes enriched for or substantially devoid of sinoatrial node-like pacemaker cardiomyocytes (SANLCM) from human pluripotent stem cells (hPSCs), and methods of use thereof.
-
4.发明公开METHODS AND COMPOSITIONS FOR GENERATING EPICARDIUM CELLS 审中-公开VERFAHREN UND ZUSAMMENSETZUNGEN ZUR ERZEUGUNG EPIKARDZELLEN
公开(公告)号：EP3044310A4
公开(公告)日：2017-06-21
申请号：EP14844375
申请日：2014-09-12
Applicant: UNIV HEALTH NETWORK
Inventor： KELLER GORDON , WITTY ALEC DRAKE , KATTMAN STEVEN JAMES
CPC classification number: C12N5/0657 , C12N2501/115 , C12N2501/155 , C12N2501/16 , C12N2501/165 , C12N2501/40 , C12N2506/45 , C12Q1/6881 , C12Q2600/158 , G01N33/5023 , G01N33/5044 , G01N33/5061
-
5.发明公开METHODS FOR GENERATING HEPATOCYTES AND CHOLANGIOCYTES FROM PLURIPOTENT STEM CELLS 审中-公开用于生产和肝的胆管OFF多能干细胞
公开(公告)号：EP2956540A4
公开(公告)日：2016-08-03
申请号：EP14751044
申请日：2014-02-18
Applicant: UNIV HEALTH NETWORK , HOSPITAL FOR SICK CHILDREN
Inventor： KELLER GORDON , OGAWA SHINICHIRO , GHANEKAR ANAND , BEAR CHRISTINE , KAMATH BINITA M , OGAWA MINA , SURAPISITCHAT JAMES
IPC: C12N5/071 , A61K35/12 , A61K35/407 , A61P1/16 , C12N5/0735 , C12Q1/02
CPC classification number: C12N5/067 , A61K35/407 , C12N5/0679 , C12N2501/01 , C12N2501/115 , C12N2501/119 , C12N2501/12 , C12N2501/155 , C12N2501/16 , C12N2501/237 , C12N2501/415 , C12N2501/42 , C12N2501/724 , C12N2501/727 , C12N2501/999 , C12N2502/00 , C12N2502/14 , C12N2503/02 , C12N2506/02 , C12N2506/45
Abstract: Methods for producing hepatocyte and/or cholangiocyte lineage cells from pluripotent stem cells, the method comprising (a) specifying the extended nodal agonist treated induced endodermal cell population to obtain a cell population comprising hepatocyte and/or cholangiocyte progenitors by contacting the extended nodal agonist treated induced endodermal cell population with specification media comprising a FGF agonist and a BMP4 agonist and/or active conjugates and/or fragments thereof; (b) inducing maturation, and optionally further lineage specification and/or expansion of the hepatocyte and/or cholangiocyte progenitors of the cell population to obtain a population comprising hepatocyte lineage cells such as hepatoblasts, hepatocytes and/or cholangiocytes, the inducing maturation step comprising generating aggregates of the cell population. Optionally, the method also comprises activating the cAMP pathway within the aggregates and forming co-aggregates.
-
Patent Agency Ranking6.发明公开POPULATIONS OF HEMATOPOIETIC PROGENITORS AND METHODS OF ENRICHING STEM CELLS THEREFOR 审中-公开造血VORLÄUFENR和方法富集干细胞种的种群
公开(公告)号：EP2782996A4
公开(公告)日：2015-04-08
申请号：EP12851240
申请日：2012-11-21
Applicant: UNIV HEALTH NETWORK , SUNNYBROOK RES INST
Inventor： KELLER GORDON , ZUNIGA-PFLUCKER JUAN CARLOS , KENNEDY MARION J , STURGEON CHRISTOPHER MICHAEL , DITADI ANDREA , AWONG GENEVE SHEANDRA
IPC: C12N5/0789 , C12N5/071 , C12Q1/24 , G01N33/569
CPC classification number: C12N5/0647 , C12N2500/24 , C12N2500/35 , C12N2500/38 , C12N2501/105 , C12N2501/115 , C12N2501/125 , C12N2501/14 , C12N2501/145 , C12N2501/155 , C12N2501/16 , C12N2501/165 , C12N2501/2303 , C12N2501/2306 , C12N2501/2307 , C12N2501/2311 , C12N2501/26 , C12N2502/1394 , C12N2506/02 , C12N2506/45 , G01N33/56972 , G01N2333/70596
Abstract: There is described herein a method of enriching a population of stem cells for hematopoietic progenitors. The method comprises inducing hematopoietic differentiation in a population of human embryonic stem cells or human induced pluripotent stem cells; sorting the population based on expression of CD43 and at least one of CD34, CD31 and CD144; and selecting a fraction that is at least one of CD34+CD43−, CD31+CD43− and CD144+CD43−. Also provided are populations of hematopoietic progenitors obtained by the methods described herein.
-
7.发明公开METHODS FOR ENRICHING PLURIPOTENT STEM CELL-DERIVED CARDIOMYOCYTE PROGENITOR CELLS AND CARDIOMYOCYTE CELLS BASED ON SIRPA EXPRESSION 审中-公开工艺富集OFF多能干得心肌PRE-细胞和SIRPA表达进行心肌细胞的
公开(公告)号：EP2609194A4
公开(公告)日：2014-02-19
申请号：EP11819236
申请日：2011-08-26
Applicant: UNIV HEALTH NETWORK
Inventor： KELLER GORDON , CRAFT APRIL M , DUBOIS NICOLE C
IPC: C12N5/077 , C12N5/0775 , C12Q1/04 , C12Q1/68 , G01N33/567
CPC classification number: C12N5/0657 , C12N2501/115 , C12N2501/155 , C12N2501/16 , C12N2501/165 , C12N2501/415 , C12N2506/02 , C12N2506/45 , C12Q1/6881 , C12Q2600/158
Abstract: The present invention relates to methods for enriching pluripotent stem cell-derived cardiomyocyte progenitor cells and cardiomyocyte cells based on SIRPA expression.
-
公开(公告)号：NZ716860A
公开(公告)日：2022-07-01
申请号：NZ71686014
申请日：2014-09-12
Applicant: UNIV HEALTH NETWORK
Inventor： KELLER GORDON , WITTY ALEC DRAKE , KATTMAN STEVEN JAMES
Abstract: Provided are methods and products for obtaining cardiovascular lineage cells from hPSCs. The method for obtaining a cardiomyocyte lineage or an epicardial lineage cell population from human pluripotent stem cells (hPSCs) comprises one or more of the following steps: (a) contacting BMP component primed hPSCs with a cardiovascular mesoderm programming cocktail suitable for inducing the hPSCs to differentiate to a cardiovascular mesoderm cell population under conditions suitable for the programming cocktail to penetrate the hPSCs and culturing the contacted hPSCs for a period of time to generate a KDR+ and PDGFRalpha+ cardiovascular mesoderm cell population; (b) contacting the cardiovascular mesoderm cell population with a cardiovascular progenitor specification cocktail suitable to specify a NKX2-5+ or WT1+ cardiovascular progenitor cell population under conditions suitable for the specification cocktail to penetrate the cardiovascular mesoderm cell population and culturing the contacted cardiovascular mesoderm cell population for a period of time to generate a NKX2-5+ or WT1+ cardiovascular progenitor cell population; and (d) contacting the cardiovascular progenitor cell population with a maturation cocktail under conditions suitable for the maturation cocktail to penetrate the cardiovascular progenitor cell population and culturing the contacted cardiovascular progenitor population for a period of time to produce a cardiovascular population optionally cardiomyocyte lineage cells expressing cardiac troponin T (cTnT) and/or SIRPA and/or epicardial lineage cells expressing WT1. In a particular embodiment of the invention is an ex-vivo method of specifying a Wilm’s tumor protein 1 positive (WT1+) population comprising the step of contacting an hPSC-derived KDR+ and PDGFRalpha+ cardiovascular mesoderm cell population with a cardiovascular progenitor specification cocktail comprising human BMP4 at a concentration of between 0.63 ng/ml and 10 ng/ml. In addition this method optionally includes i) causing the cell population to progress toward a vascular smooth muscle-like fate by treating it with human TGFβ-1 or human TGFβ-1 followed by human bFGF; or (ii) causing the cell population to progress toward a fibroblast-like fate by treating it with human bFGF.
-
公开(公告)号：CA3142666A1
公开(公告)日：2020-12-10
申请号：CA3142666
申请日：2020-06-03
Applicant: UNIV HEALTH NETWORK
Inventor： OGAWA SHINICHIRO , OGAWA MINA , KELLER GORDON
IPC: C12N5/071 , A61K35/407 , A61P1/16 , C12N5/00
Abstract: Provided herein are methods of making and using a number of different types of liver cells.
-
10.发明专利
公开(公告)号：AU2020204058A1
公开(公告)日：2020-07-09
申请号：AU2020204058
申请日：2020-06-18
Applicant: UNIV HEALTH NETWORK
Inventor： KELLER GORDON , CRAFT APRIL M
Abstract: Abstract Methods and compositions for generating chondrocyte lineage cells and/or cartilage like tissue A method for generating chondrocytes and/or cartilage, optionally articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue and/or hypertrophic chondrocyte like cells and/or cartilage like tissue, the method comprising: a. culturing a primitive streak-like mesoderm population, optionally a CD56+, PDGFRalpha+ KDR- primitive streak-like mesoderm population, with a paraxial mesoderm specifying cocktail comprising: i. a FGF agonist; ii. a BMP inhibitor; optionally Noggin, LDN-193189, Dorsomorphin; and iii. optionally one or more of a TGFbeta inhibitor, optionally SB431524; and a Wnt inhibitor, optionally DKK1, IWP2, or XAV939; to specify a paraxial mesoderm population expressing cell surface CD73, CD105 and/or PDGFR-beta; b. generating a chondrocyte precursor population comprising: i. culturing the paraxial mesoderm population expressing CD73, CD105 and/or PDGFR-beta at a high cell density optionally in serum free or serum containing media; ii. culturing the high cell density CD73+, CD105+ and/or PDGFRbeta+ paraxial mesoderm population with a TGFbeta3 agonist in serum free media to produce a high cell density Sox9+, collagen 2+ chondrocyte precursor population; and c. either i. culturing the high cell density Sox9+, collagen 2+ chondrocyte precursor population with the TGFbeta3 agonist for an extended period of time to produce an articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue; or ii. culturing the high cell density Sox9+ collagen2+ chondrocyte precursor population with a BMP4 agonist for an extended period of time to produce a hypertrophic chondrocyte like cells and/or cartilage like tissue.
-
-
-
-
-
-
-
-
-
Search Results
69
records
(took 0.026 seconds)
